Mazindol augmentation of antipsychotic treatment for schizophrenic patients with comorbid cocaine abuse or dependence: A preliminary double-blind, randomized, placebo-controlled trial

Journal of Dual Diagnosis

Volumn 1, Issue 1, 2004, Pages 37-47

  Perry Jr , Edward B ^a   Gil, Roberto ^b   Miles, Deborah ^b   Brenner, Louise ^b   MacDougall, Lisa ^b   Johnson, Robin ^b   Degen, Kathleen ^b   Gueorguieva, Ralitza ^b   Petrakis, Ismene L ^b   Krystal, John H ^b   D'Souza, D Cyril ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

Antipsychotic agents; Cocaine; Dopamine; Mazindol; Schizoaffective disorder; Schizophrenia

Indexed keywords

COCAINE; MAZINDOL; NEUROLEPTIC AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; EXTRAPYRAMIDAL SYMPTOM; GROUP THERAPY; HUMAN; MOTIVATION; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME; URINALYSIS;

EID: 24144456995     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1300/J374v01n01_04     Document Type: Article

References (40)

1. Wilkins JN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 1997;23(2):215-28.
2. Smelson DA, Davis CW, Eisenstein N, Engelhart C, Williams J, Losonczy MF, et al. Cognitive disparity in schizophrenics with and without cocaine dependency. J Subst Abuse Treat 2003;24(1):75-9.
3. Aeberli P, Eden P, Gogerty JH, Houlihan WJ, Penberthy C. 5-aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ols. A novel class of anorectic agents. J Med Chem 1975;18(2):177-82.
4. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237(4819):1219-23.
5. Javitch JA, Blaustein RO, Snyder SH. [3H]mazindol binding associated with neuronal dopamine uptake sites in corpus striatum membranes. Eur J Pharmacol 1983;90(4):461-2.
6. Gevaerd MS, Takahashi RN. Interaction of mazindol with alcohol in mice. Addict Biol 1996;1(3):303-7.
7. Rothman RB. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 1990;46(20):PL17-21.
8. Hadler AJ. Mazindol, a new non-amphetamine anorexigenic agent. J Clin Pharmacol New Drugs 1972;12(11):453-8.
9. Chait LD, Uhlenhuth EH, Johanson CE. Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther 1987;242(3):777-83.
10. Mansbach RS, Balster RL. Effects of mazindol on behavior maintained or occasioned by cocaine. Drug Alcohol Depend 1993;31(2):183-91.
11. Pickworth WB, Klein SA, Bunker EB, Henningfield JE. Assessment of mazindol for abuse liability. NIDA Res Monogr 1991;105:443.
12. Berger P, Gawin F, Kosten TR. Treatment of cocaine abuse with mazindol. Lancet 1989;1(8632):283.
13. Kosten TR, Steinberg M, Diakogiannis IA. Crossover trial of mazindol for cocaine dependence. Am J Addict 1993;2(2):161-164.
14. Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 1995;21(4):469-81.
15. Margolin A, Avants SK, Malison RT, Kosten TR. High- and low-dose mazindol for cocaine dependence in methadone-maintained patients: A preliminary evaluation. Subst Abuse 1997;18(3):125-131.
16. Stine SM, Krystal JH, Kosten TR, Charney DS. Mazindol treatment for cocaine dependence. Drug Alcohol Depend 1995;39(3):245-52.
17. Preston KL, Sullivan JT, Berger P, Bigelow GE. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J Pharmacol Exp Ther 1993;267(1):296-307.
18. Krumholz WV, White L. Clinical evaluation of mazindol in chronic schizophrenics. Curr Ther Res Clin Exp 1970;12(9):609-10.
19. Seibyl J, Krystal JH, Johnson R, Brenner L, Heninger G, Charney DS. Mazindol augmentation of typical antipsychotics in negative symptom schizophrenics (Abstract 148.6). Abs Soc Neuroscience 1991;17:354.
20. Seibyl J, Erdos J, Karper L, Johnson R, Brenner L, Heninger G, et al. Long-term mazindol augmentation of neuroleptic in negative schizophrenia (Abstract 95.4). Abs Soc Neuroscience 1992;18:202.
21. Carpenter WT, Jr., Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E. Mazindol treatment of negative symptoms. Neuropsychopharmacology 2000;23(4):365-74.
22. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50(2):71-83.
23. Krystal JH, D'Souza DC, Madonick S, Petrakis IL. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 1999;35 Suppl:S35-49.
24. Self DW, Barnhart WJ, Lehman DA, Nestler EJ. Opposite modulation of cocaine-seeking behavior by D1-and D2-like dopamine receptor agonists. Science 1996;271(5255):1586-9.
25. Seibyl JP, Brenner L, Krystal JH, Johnson R, Charney DS. Mazindol and cocaine addiction in schizophrenia. Biol Psychiatry 1992;31(11):1179-81.
26. Spitzer R, Williams J, Gibbon M, First M. User's Guide for the Structured Clinical Interview for DSM-III-R (SCID). Washington, DC: American Psychiatric Press; 1990.
27. Ziedonis D, Fisher W. Assessment and treatment of comorbid substance abuse in individuals with schizophrenia. Psychiatr Ann 1994;24:477-483.
28. Gawin FH, Kleber HD. Cocaine abuse treatment. Open pilot trial with desipramine and lithium carbonate. Arch Gen Psychiatry 1984;41(9):903-9.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-76.
30. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat 1968;5(2):257-82.
31. Guy We. ECDEU assessment manual for psychopharmacology. Washington: U.S. Department of Health, Education and Welfare; 1976.
32. Tanda G, Pontieri FE, Frau R, Di Chiara G. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci 1997;9(10):2077-85.
33. Carboni E, Tanda GL, Frau R, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990;55(3):1067-70.
34. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003;9(5):404-16.
35. Serper MR, Alpert M, Trujillo M. Recent cocaine use decreases negative signs in acute schizophrenia: a case study over two consecutive admissions. Biol Psychiatry 1996;39(9):816-8.
36. Serper MR, Alpert M, Richardson NA, Dickson S, Allen MH, Werner A. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry 1995;152(10):1464-9.
37. Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP. Effect of cocaine self-administration on striatal dopamine D1 receptors in rhesus monkeys. Synapse 1998;28(1):1-9.
38. Malison R, Best S, Wallace E, van Dyck C, Zoghbi S, Zea-Ponce Y, et al. SPECT imaging of dopamine transporters in cocaine dependent and healthy control subjects with [123I]b-CIT. J Nucl Med 1995;36:31P.
39. Malison R, Best S, Zoghbi S, Zea-Ponce Y, Baldwin RM, Charney DS, et al. SPECT imaging of dopamine transporters during sustained cocaine abstinence with [123I]b-CIT. J Nucl Med 1996;37:44P.
40. Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, et al. [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl) 1998;137(4):321-5.